BNTC revenueQ3 2026$0
- FY YoY
- -100.0%
BNTC revenue was $0 in fiscal Q3 2026 (ended Mar 31, 2026), compared with $0 a year earlier. For the full fiscal 2024 it was $0, down 100.0% from fiscal 2023.
Benitec Biopharma Inc. (BNTC) financials
For fiscal 2026 (ended Jun 30, 2026), Benitec Biopharma Inc. reported -$45.55M of net income.
- Net income, FY2026
- -$45.55M
- Free cash flow, FY2026
- -$16.62M
- EPS, diluted, FY2026
- -$0.98
- Cash
- $179.97M
- Market cap
- $344.4M
FY2019FY2024
FY2019FY2026
FY2019FY2026
BNTC revenue and earnings growth
BNTC net incomeQ4 2026-$12.81M
BNTC net income was -$12.81M in fiscal Q4 2026 (ended Jun 30, 2026), compared with -$8.80M a year earlier. For the full fiscal 2026 it was -$45.55M, compared with -$37.92M in fiscal 2025.
BNTC EPSQ4 2026-$0.26
BNTC diluted EPS was -$0.26 in fiscal Q4 2026 (ended Jun 30, 2026), compared with -$0.21 a year earlier. For the full fiscal 2026 it was -$0.98, compared with -$1.05 in fiscal 2025.
BNTC free cash flowQ4 2026-$5.02M
BNTC free cash flow was -$5.02M in fiscal Q4 2026 (ended Jun 30, 2026), compared with -$8.21M a year earlier. For the full fiscal 2026 it was -$16.62M, compared with -$23.61M in fiscal 2025.
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $75.0K | $73.0K | $59.0K | $102.0K | $12.20M |
| Research and development | $23.39M | $18.33M | $15.61M | $12.77M | $11.27M | $7.02M | $3.00M | $4.57M |
| Selling, general and admin | $27.80M | $23.43M | $6.99M | $6.38M | $6.65M | $6.51M | $5.57M | $4.61M |
| Operating income | -$51.19M | -$41.77M | -$22.49M | -$19.08M | -$17.85M | -$13.60M | -$8.28M | $2.58M |
| Income tax | $0 | - | - | - | - | - | - | - |
| Net income | -$45.55M | -$37.92M | -$21.75M | -$19.56M | -$18.21M | -$13.88M | -$8.27M | $2.61M |
| EPS, basic | -$0.98 | -$1.05 | -$1.22 | -$2.17 | -$5.83 | -$8.45 | -$21.18 | $7.98 |
| EPS, diluted | -$0.98 | -$1.05 | -$1.22 | -$2.17 | -$5.83 | -$8.45 | -$21.18 | $7.98 |
| Diluted shares | 46.6M | 36.2M | 18.4M | 9.0M | 3.1M | 1.6M | 390,456.147 | 327,586.618 |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $179.97M | $97.74M | $50.93M | $2.49M | $4.08M | $19.78M | $9.82M | $15.72M |
| Current assets | $181.69M | $98.52M | $51.67M | $3.73M | $4.82M | $20.61M | $10.81M | $18.76M |
| Total assets | $182.62M | $99.59M | $52.21M | $4.46M | $5.97M | $21.38M | $11.59M | $19.23M |
| Current liabilities | $5.34M | $1.80M | $4.92M | $3.98M | $2.53M | $1.37M | $1.14M | $2.64M |
| Total liabilities | $5.61M | $2.30M | $4.96M | $4.26M | $3.09M | $1.37M | $1.35M | $2.64M |
| Shareholders' equity | $177.01M | $97.30M | $47.25M | $202.0K | $2.88M | $20.01M | $10.24M | $16.59M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.52M | -$23.59M | -$19.40M | -$18.01M | -$15.90M | -$12.83M | -$7.54M | $4.79M |
| Capital expenditures | $105.0K | $18.0K | $179.0K | $1.0K | $13.0K | $221.0K | $95.0K | $404.0K |
| Free cash flow | -$16.62M | -$23.61M | -$19.58M | -$18.01M | -$15.91M | -$13.05M | -$7.63M | $4.39M |
| Investing cash flow | -$105.0K | -$18.0K | -$179.0K | -$1.0K | -$13.0K | -$221.0K | -$94.0K | -$400.0K |
| Financing cash flow | $98.98M | $70.48M | $68.03M | $16.02M | - | $22.52M | $1.77M | - |
| Stock-based compensation | $26.41M | $17.43M | $830.0K | $452.0K | $870.0K | $634.0K | $237.0K | $672.0K |
| Depreciation and amortization | $58.0K | $66.0K | $87.0K | $136.0K | $167.0K | $231.0K | $190.0K | $158.0K |
Key ratios
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -100.0% | 2.7% | 23.7% | -42.2% | -99.2% | - |
| Operating margin | - | - | - | -25441.3% | -24457.5% | -23044.1% | -8118.6% | 21.2% |
| Net margin | - | - | - | -26082.7% | -24942.5% | -23528.8% | -8111.8% | 21.4% |
| Free cash flow margin | - | - | - | -24017.3% | -21797.3% | -22123.7% | -7480.4% | 36.0% |
| Return on equity | -25.7% | -39.0% | -46.0% | -9684.2% | -631.8% | -69.4% | -80.8% | 15.7% |
| Return on assets | -24.9% | -38.1% | -41.7% | -438.2% | -304.8% | -64.9% | -71.4% | 13.6% |
| Current ratio | 34.00 | 54.67 | 10.49 | 0.94 | 1.90 | 15.05 | 9.51 | 7.10 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $0 | $0 | $0 | - | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $7.89M | $6.30M | $5.83M | $3.37M | $2.87M | $6.50M | $5.38M | $3.58M | $3.51M | $2.57M | $5.10M | $4.43M |
| Selling, general and admin | $6.54M | $7.28M | $7.54M | $6.43M | $6.97M | $8.84M | $5.42M | $2.21M | $2.04M | $1.58M | $1.82M | $1.55M |
| Operating income | -$14.43M | -$13.58M | -$13.38M | -$9.80M | -$9.83M | -$15.34M | -$10.80M | -$5.79M | -$5.55M | -$4.14M | -$6.93M | -$5.87M |
| Net income | -$12.81M | -$11.94M | -$11.84M | -$8.96M | -$8.80M | -$14.50M | -$9.55M | -$5.06M | -$4.72M | -$4.28M | -$6.80M | -$5.95M |
| EPS, basic | -$0.26 | -$0.24 | -$0.26 | -$0.22 | -$0.21 | -$0.38 | -$0.26 | -$0.18 | - | -$0.23 | -$0.41 | -$0.47 |
| EPS, diluted | -$0.26 | -$0.24 | -$0.26 | -$0.22 | -$0.21 | -$0.38 | -$0.26 | -$0.18 | - | -$0.23 | -$0.41 | -$0.47 |
| Diluted shares | - | 49.4M | 46.0M | 41.5M | 41.2M | 38.6M | 37.3M | 27.9M | - | 18.3M | 16.7M | 14.0M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $179.97M | $184.76M | $188.79M | $94.48M | $97.74M | $103.45M | $78.34M | $67.91M | $50.93M | $14.16M | $20.39M | $25.88M |
| Current assets | $181.69M | $186.02M | $189.59M | $95.08M | $98.52M | $104.01M | $78.71M | $68.33M | $51.67M | $14.37M | $20.80M | $26.41M |
| Total assets | $182.62M | $187.00M | $190.68M | $96.03M | $99.59M | $105.21M | $79.07M | $68.77M | $52.21M | $15.00M | $21.35M | $27.05M |
| Current liabilities | $5.34M | $3.27M | $2.80M | $2.02M | $1.80M | $7.03M | $3.09M | $4.55M | $4.92M | $3.44M | $5.75M | $4.53M |
| Total liabilities | $5.61M | $3.67M | $3.32M | $2.43M | $2.30M | $7.64M | $3.13M | $4.59M | $4.96M | $3.50M | $5.88M | $4.75M |
| Shareholders' equity | $177.01M | $183.33M | $187.36M | $93.60M | $97.30M | $97.57M | $75.94M | $64.18M | $47.25M | $11.50M | $15.47M | $22.31M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.94M | -$4.45M | -$3.78M | -$3.35M | -$8.21M | -$3.09M | -$7.70M | -$4.59M | -$3.29M | -$6.17M | -$5.37M | -$4.58M |
| Capital expenditures | $79.0K | $15.0K | - | - | $0 | $6.0K | - | - | $0 | - | - | - |
| Free cash flow | -$5.02M | -$4.47M | - | - | -$8.21M | -$3.09M | - | - | -$3.29M | - | - | - |
| Investing cash flow | -$79.0K | -$15.0K | -$11.0K | $0 | $0 | -$6.0K | -$12.0K | $0 | $0 | -$179.0K | $0 | $0 |
| Financing cash flow | $241.0K | $506.0K | $98.23M | $0 | $2.74M | $28.21M | $17.87M | $21.66M | $40.07M | $0 | $39.0K | $27.92M |
| Stock-based compensation | $6.26M | $7.59M | $7.38M | $5.18M | $6.11M | $7.74M | $3.14M | $435.0K | $454.0K | $192.0K | $93.0K | $91.0K |
| Depreciation and amortization | $17.0K | $14.0K | $14.0K | $13.0K | $14.0K | $13.0K | $14.0K | $25.0K | $26.0K | $25.0K | $17.0K | $19.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | -100.0% | -100.0% | -100.0% | - |
| Current ratio | 34.00 | 56.82 | 67.69 | 46.95 | 54.67 | 14.80 | 25.48 | 15.01 | 10.49 | 4.18 | 3.62 | 5.83 |
Source: XBRL data Benitec Biopharma Inc. files with the SEC, latest filing dated Sep 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-17, first reported Sep 21, 2023; 13-for-2, first reported May 14, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
BNTC peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BNTC | - | - | -$45.55M | - | $344.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
BNTC FAQ
7 questionsIs BNTC profitable?
No. Benitec Biopharma Inc. reported a net loss of $45.55M for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does BNTC have?
Benitec Biopharma Inc. reported $179.97M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is BNTC revenue growing?
Benitec Biopharma Inc.'s revenue changed -100.0% in fiscal 2024, to $0.What is BNTC free cash flow?
Benitec Biopharma Inc. generated -$16.62M of free cash flow for fiscal 2026 (ended Jun 30, 2026), which is operating cash flow of -$16.52M less capital expenditures.What is BNTC earnings per share?
Diluted earnings per share were -$0.98 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did BNTC last report financial results?
The latest statements here come from Benitec Biopharma Inc.'s 10-K filed on Sep 14, 2026, covering the period ended Jun 30, 2026.Where does this BNTC financial data come from?
Quantisnow builds these statements from the structured XBRL data Benitec Biopharma Inc. files with the SEC. It is provided for information only and is not investment advice.